US Genomics Powerhouse Embraces Protein Analysis, Accelerates Proteomics Strategy

On January 30, U.S. genomics company Illumina, Inc. (ILMN) completed its acquisition of proteomics firm SomaLogic and certain assets of Standard BioTools. The deal comprises $350 million in cash and up to $75 million in performance-based payments—roughly ₩450 billion and ₩100 billion, respectively. Illumina plans to integrate SomaLogic’s SomaScan® assay and SomaSignal™ tests into its next-generation sequencing portfolio and onto its Dragon and Connected Multi-Omics platforms, strengthening its proteomics and multi-omics capabilities.

Having reported provisional fourth-quarter and full-year 2025 results—showing a 2% year-over-year rise in revenues outside China to about $4.1 billion—Illumina is set to release its final figures after the market close on February 5 (local time). Since reaching a 52-week high on January 22, the stock has entered a corrective phase with increased volatility through early February.

A global leader in DNA sequencing and microarray technologies, Illumina supplies next-generation sequencing platforms for research, clinical medicine, cancer diagnostics, reproductive health, and agriculture. In the rapidly expanding proteomics and multi-omics market, this acquisition underscores intensifying competition among genomics firms vying to broaden their technology and platform offerings.